Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0014819,
umls-concept:C0014822,
umls-concept:C0019046,
umls-concept:C0035286,
umls-concept:C0086418,
umls-concept:C0205216,
umls-concept:C0205307,
umls-concept:C0443315,
umls-concept:C0456205,
umls-concept:C0681850,
umls-concept:C1280500,
umls-concept:C1527148,
umls-concept:C1550501,
umls-concept:C1550605,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2697811
|
pubmed:issue |
5
|
pubmed:dateCreated |
1994-6-29
|
pubmed:abstractText |
The present study evaluates the properties of the reticulocytes produced in healthy volunteers after treatment with different regimens of recombinant human erythropoietin (r-HuEPO). Twenty-four subjects were randomly assigned to one of three different subcutaneous (SC) r-HuEPO (Protcrit; Ortho Biotech) administration protocols (I: 300 U/kg on days 1, 4, 7, 10; II: 400 U/kg on days 1, 5, 9; III: 600 U/kg on days 1, 10) with oral iron supplementation (Niferex; 150 mg, twice a day). The characteristics of the reticulocytes produced were examined with a flow cytometry method that allows measurements of individual reticulocyte cell volume, hemoglobin concentration, and hemoglobin content. Administration of SC r-HuEPO was associated with a significant increase in the production of reticulocytes. The hemoglobin content of reticulocytes (CHr, in picograms of hemoglobin per cell) in the three groups was 28.5 +/- 1.0, 28.2 +/- 0.5, and 28.5 +/- 1.3, respectively, at baseline, decreased to 24.6 +/- 1.6 (p < 0.001), 24.5 +/- 2.3 (p < 0.001), and 27.5 +/- 1.8 (not significant) at day 10, and returned to baseline after r-HuEPO was discontinued (28.8 +/- 0.9, 28 +/- 0.8, and 28.8 +/- 1.4, respectively, at day 22). The percentage of reticulocytes with cell hemoglobin content less than 23 pg was taken as an indicator of iron-deficient erythropoiesis. At baseline, 5.6% +/- 2.7%, 6.9% +/- 3.4%, and 8.3% +/- 3.8% of reticulocytes had less than 23 pg hemoglobin in groups I, II, and III, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-2143
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
123
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
660-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8195672-Erythropoiesis,
pubmed-meshheading:8195672-Erythropoietin,
pubmed-meshheading:8195672-Hemoglobins,
pubmed-meshheading:8195672-Humans,
pubmed-meshheading:8195672-Injections, Subcutaneous,
pubmed-meshheading:8195672-Iron,
pubmed-meshheading:8195672-Male,
pubmed-meshheading:8195672-Osmolar Concentration,
pubmed-meshheading:8195672-Recombinant Proteins,
pubmed-meshheading:8195672-Reference Values,
pubmed-meshheading:8195672-Reticulocytes
|
pubmed:year |
1994
|
pubmed:articleTitle |
Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis.
|
pubmed:affiliation |
Department of Pathology, Brigham and Women's Hospital.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|